Back to Search
Start Over
Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.
Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.
- Source :
-
Pharmacological research [Pharmacol Res] 2022 Jan; Vol. 175, pp. 105997. Date of Electronic Publication: 2021 Nov 24. - Publication Year :
- 2022
-
Abstract
- The immune checkpoint cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is an inhibitory regulator of T-cell mediated responses that has been investigated as target of monoclonal antibodies (mAbs) for cancer immunotherapy. The anti-CTLA-4 mAb ipilimumab represents the first immune checkpoint inhibitor that significantly improved overall survival in patients with unresectable/metastatic melanoma. The subsequent approved indications (often in the first-line setting) for melanoma and other advanced/metastatic solid tumors always require ipilimumab combination with nivolumab, an anti-programmed cell death protein 1 (PD-1) mAb. However, the improved clinical efficacy of the mAb combination is associated with increased immune-related adverse events, which might require treatment discontinuation even in responding patients. This drawback is expected to be overcome by the recent development of anti-CTLA-4 probodies proteolitycally activated in the tumor microenvironment and bispecific molecules targeting both CTLA-4 and PD-1, whose co-expression is characteristic of tumor-infiltrating T cells. These molecules would preferentially stimulate immune responses against the tumor, reducing toxicity toward normal tissues.<br /> (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Subjects :
- Animals
Antibodies, Bispecific immunology
Antineoplastic Agents, Immunological adverse effects
Humans
Immunotherapy adverse effects
Ipilimumab adverse effects
Neoplasms immunology
Tumor Microenvironment immunology
Antineoplastic Agents, Immunological therapeutic use
CTLA-4 Antigen antagonists & inhibitors
Ipilimumab therapeutic use
Neoplasms drug therapy
Tumor Microenvironment drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1096-1186
- Volume :
- 175
- Database :
- MEDLINE
- Journal :
- Pharmacological research
- Publication Type :
- Academic Journal
- Accession number :
- 34826600
- Full Text :
- https://doi.org/10.1016/j.phrs.2021.105997